XLVX ETF — Corgi U.S. Healthcare 2x Daily ETF

Corgi U.S. Healthcare 2x Daily ETF (XLVX)

Updated October 16, 2026.

XLVX is an ETF. its expense ratio is 0.45%. Total return is 39.2% over the past 0.4 years, 37.5 points ahead of SPY at 1.7%.

Corgi U.S. Healthcare 2x Daily ETF is a leveraged equity fund that seeks daily exposure approximately two times the performance of U.S. healthcare companies through financial derivatives such as swaps and futures, with an expense ratio of 0.45%. The fund does not have an established distribution schedule. This fund appeals to experienced traders and tactical investors seeking short-term leveraged exposure to healthcare equities, though the daily rebalancing mechanism means it is not suited for buy-and-hold strategies.

XLVX performance versus SPY

Price and return data through 2026-10-16.

Total return is 39.2% over the past 0.4 years, 37.5 points ahead of SPY at 1.7%.

XLVX key facts

Issuer

Corgi Strategies

Asset type

ETF

Asset class

Equity

Inception date

06/03/2026

Expense ratio

0.45%

Distribution frequency

None

Last close

$35.36 (as of 2026-10-16)

AUM

$629,280

Average volume

45500.0

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Corgi Strategies; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider XLVX — and who may not

It is a weaker fit for investors who need monthly cash flow (XLVX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on XLVX

• All tickers starting with X

Tagged: Leverage, Healthcare.

Frequently asked questions

More securities from Corgi Strategies.